Community Pharmacy is Changing and so is Mawdsleys

Press Release

 

13 February 2018

 

Community Pharmacy is changing and so is Mawdsleys.

 

Mawdsleys, working in conjunction with its associate company the DE Group, has completed a joint strategic review of their wholesale activities. The review has concluded that customer interests and the future prospects of both organisations would benefit if they concentrate respectively on the sectors where they have specific market expertise.

 

The DE Group has developed an efficient twice-daily delivery service from eight locations serving independent community pharmacies throughout the UK. We believe that the DE Group has the most appropriate resources and infrastructure to focus on supporting independent community pharmacy in the longer term.

 

Similarly, Mawdsleys has developed an impressive Hospital wholesale business, widely acknowledged by Hospitals as the market leader for accuracy of deliveries and customer service support.  Prioritising resource and investment into secondary care will allow Mawdsleys greater flexibility to respond proactively to future market trends in the hospital sector.

 

This strategy will begin from 1st April 2018 with the process of assimilating the Mawdsleys full line retail wholesale business into the DE Group infrastructure, allowing Mawdsleys to concentrate on fulfilling its orders and delivering enhanced bespoke solutions to Hospitals.

 

Changing times call for innovative solutions and Mawdsleys and the DE Group believe this strategic collaboration will be a positive move to secure the future interests of both companies, provide opportunities for our staff, and an improved service platform for both the Independent community pharmacy and hospital sectors.

 

The DE Group are part of the Converse Pharma Group.

 

Other latest news
https://www.mawdsleys.co.uk/news/mawdsleys-and-oncoscience-launch-a-named-patient-program-for-cimaher-nimotuzumab-in-the-uk-and-ireland/ thumbnail image Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher®

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.   Nimotuzumab has been approved for marketing in 25 different countries worldwide for a variety of…

Read more
https://www.mawdsleys.co.uk/news/were-progressing-our-sustainability-commitments/ thumbnail image We’re progressing our sustainability commitments

We are currently trialling an electric trailer refrigeration unit. The E-Cool Trailer is an all-electric, engineless, refrigeration system that converts the kinetic energy generated by the trailer axel and brakes into electricity, which is then stored in a battery pack that powers the onboard refrigeration unit that’s required for the…

Read more